Bay Colony Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bay Colony Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-6,706	Closed	-$574K	–	252
2019 Q2	$574K	Sell	6,706 -194	-3%	-$16.6K	0.37%	76
2019 Q1	$606K	Hold	6,900	–	–	0.4%	69
2018 Q4	$588K	Sell	6,900 -100	-1%	-$9.51K	0.5%	49
2018 Q3	$679K	Sell	7,000 -1,400	-17%	-$140K	0.52%	56
2018 Q2	$791K	Buy	+8,400	New	+$736K	0.56%	42

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Bay Colony Advisors's BMRN Position: Q3 2019 in Review

Bay Colony Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 6,706 shares — an estimated $574K sold.

Bay Colony Advisors first reported a position in BMRN in Q2 2018 and held it in 5 quarters. The position peaked at $791K in Q2 2018. 436 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

Bay Colony Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Bay Colony Advisors sold 6,706 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $574K.
Bay Colony Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2018 and held it in 5 quarters.
Bay Colony Advisors's BioMarin Pharmaceuticals position peaked at $791K in Q2 2018.
436 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Bay Colony Advisors's 13F filing for Q3 2019, filed 25 Oct 2019.